The Canadian Intellectual Property Office issues a Notice of Allowance to VistaGen Therapeutics (OTCQB:VSTA) for its patent application No. 2,487,058 entitled "Mesoderm and Definitive Endoderm Cell Populations." The company has an exclusive license to the patent from the Icahn School of Medicine at Mount Sinai in New York.
VistaGen Therapeutics Inc. is biotechnology company harnessing the revolutionary power of human pluripotent stem cell technology for drug rescue and cell therapy. <br /><br />VistaGen's drug rescue activities involve the combination of its human pluripotent stem cell technology with modern...More